Bioventus Inc. (NYSE:BVS) Shares Bought by Driehaus Capital Management LLC

Driehaus Capital Management LLC grew its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 33.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,119,855 shares of the company's stock after purchasing an additional 282,341 shares during the period. Driehaus Capital Management LLC owned approximately 1.38% of Bioventus worth $11,758,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in BVS. Vanguard Group Inc. lifted its holdings in shares of Bioventus by 18.7% in the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company's stock valued at $25,852,000 after acquiring an additional 388,174 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Bioventus by 38.7% in the 4th quarter. American Century Companies Inc. now owns 884,673 shares of the company's stock worth $9,289,000 after purchasing an additional 246,645 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Bioventus by 228.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company's stock valued at $3,032,000 after acquiring an additional 176,442 shares during the period. BNP Paribas Financial Markets bought a new position in Bioventus in the fourth quarter worth about $1,659,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Bioventus by 55.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 427,422 shares of the company's stock valued at $4,488,000 after purchasing an additional 152,311 shares during the last quarter. 62.94% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on BVS shares. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the company a "buy" rating in a research note on Wednesday, May 7th. Canaccord Genuity Group reissued a "buy" rating and set a $15.00 price target on shares of Bioventus in a research report on Monday, March 17th.

Bioventus Price Performance

Shares of NYSE:BVS traded up $0.13 during midday trading on Thursday, reaching $6.51. 384,229 shares of the company's stock traded hands, compared to its average volume of 453,444. Bioventus Inc. has a 1 year low of $5.28 and a 1 year high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The company has a fifty day simple moving average of $8.22 and a two-hundred day simple moving average of $9.96. The company has a market cap of $533.05 million, a P/E ratio of -10.66 and a beta of 0.95.

Insider Buying and Selling at Bioventus

In other news, CFO Mark Leonard Singleton sold 6,498 shares of Bioventus stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $66,214.62. Following the completion of the transaction, the chief financial officer now owns 118,817 shares in the company, valued at approximately $1,210,745.23. This trade represents a 5.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Anthony D'adamio sold 4,380 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares of the company's stock, valued at approximately $1,204,233.82. The trade was a 3.57% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,208 shares of company stock worth $226,138. Insiders own 32.90% of the company's stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.